I think Roche’s leveraging the balance sheet to own 100% of Genentech instead of 56% was the right thing to do despite the recent defections and clinical setbacks.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”